Margret B. Einarson, PhD

Margret Einarson, Ph.D.

Research Associate Professor

Manager, High Throughput Screening Facility

Research Program

Educational Background

  • PhD, Molecular Biology, Weill Cornell Graduate School of Medical Sciences –Sloan Kettering Institute, New York, NY 1995
  • BS, Bates College, Lewiston, ME, 1988

Research Facility

High Throughput Screening Facility

Research Interests

  • The HTSF offers expertise and specialized technology platforms providing support for translational projects within laboratory and clinic-based research programs
  • Provide education, expertise and instrumentation for researchers to employ high throughput approaches
  • Assist investigators to execute high throughput screens using small molecule and RNAi libraries to understand and target cellular pathways to identify potential cancer therapeutics
  • Provide support and materials for grant and publication submission

Lab Overview

The High Throughput Screening Facility (HTSF) provides a resource for investigators to incorporate high throughput approaches and technology platforms for the advancement of translational research programs. In my role as Manager of the HTSF, my aim is to enable each investigator to utilize the reagents and technologies in the facility to further the overall research program in their individual laboratory.  Towards this end, I provide consultation on screening projects and assist in the development and performance of small molecule and RNAi screens. In addition, the HTSF provides unique instrumentation on the FCCC campus that can be utilized in both HTS and non-screening projects.  For investigators seeking more limited use of instrumentation, I offer advice and training to their laboratory personnel to allow them to select and apply optimal applications of the HTS technology for their experiments of interest.  In addition, I coordinate between facilities for HTSF projects (such as the Biosample Repository or the Biostatistics Facility) to assist researchers to move their science forward as efficiently as possible.  In another role, I provide support of clinical investigators, supporting the development and implementation of research correlates for clinical studies.

Lab Description

The HTSF offers expertise and specialized technology platforms for translational projects within laboratory and clinically based research programs.  Examples of recent supported screening projects are listed under Publications.  Specific resources and instrumentation available for screening include:

Libraries

  • RNAi
  • Human siGenome siRNA library – targeting 22,000 genes
  • Small molecule
  • ChemDiv Diverse set – 50,000 structurally diverse compounds
  • Johns Hopkins Clinical Compound collection- 1514 FDA approved drugs
  • ICCB Known Bioactives – 470 compounds with biological activity and known targets

Technology platforms

  • BioPlex 200: multiplexed biomarker analyzer
  • Bead-based immunoassay allows analysis of multiple markers in a variety of experimental samples (including serum, plasma, cell lysates) yielding quantitative measures of biomarkers of interest.
  • ImageXpress micro automated microscope and image analysis software
  • Automated microscope for unbiased image acquisition. Images from slides, 96 and 384 well plates. Colors include \: DAPI, FITC, Red, Far Red and GFP. Objectives include 4X, 10X, 20X, 40X and 60X. Images acquired on the IXM or other microscopes can be analyzed with over 10 preset modules.
  • Perkin Elmer Envision Multilabel plate reader
  • Plate reader equipped for absorbance, fluorescence, luminescence, HTRF, FP and BRET and FRET.
  • Guava EasyCyte
  • 96 well automated cytometer
  • Liquid handlers
  • 96 and 384 well compatible automated liquid handlers including: Cybi Well Vario, BioTek Precision XS, Matrix Wellmate.

Misc

  • Assay Services
  • High Throughput Screening Facility

    The HTSF provides equipment, expertise, and direct services that enable investigators to address novel areas of translational research that would be difficult or impossible to pursue without the liquid handling and automated imaging, optimized assays, reagents and experience housed within the Facility.

    Selected Publications

    Ye S, Sharipova D, Kozinova M, Klug LR, D'Souza JW, Belinsky MG, Johnson KJ, Einarson MB, Devarajan K, Zhou Y, Litwin S, Heinrich MC, DeMatteo RP, von Mehren M, Duncan JS, Rink L. Identification of Wee1 as target in combination with avapritinib for Gastrointestinal Stromal Tumor treatment. JCI Insight. 2020 Dec 15:143474. doi: 10.1172/jci.insight.143474. Epub ahead of print. PMID: 33320833.

    Deneka AY, Einarson MB, Bennett J, Nikonova AS, Elmekawy M, Zhou Y, Lee JW, Burtness BA, Golemis EA. Synthetic Lethal Targeting of Mitotic Checkpoints in HPV-Negative Head and Neck Cancer. Cancers (Basel). 2020 Jan 28;12(2):306. doi: 10.3390/cancers12020306. PMID: 32012873; PMCID: PMC7072436.

    Kiseleva AA, Korobeynikov VA, Nikonova AS, Zhang P, Makhov P, Deneka AY, Einarson MB, Serebriiskii IG, Liu H, Peterson JR, Golemis EA. Unexpected activities in regulating ciliation contribute to off-target effects of targeted drugs. Clinical Cancer Research 2019 Jul 1;25(13):4179-4193. DOI: 10.1158/1078-0432.CCR-18-3535. PMID: 30867219 PMCID: PMC6606352

    Martin DDO, Kanuparthi PS, Holland SM, Sanders SS, Jeong HK, Einarson MB, Jacobson MA, Thomas GM. Identification of Novel Inhibitors of DLK Palmitoylation and Signaling by High Content Screening. Sci Rep. 2019 Mar 6;9(1):3632. doi: 10.1038/s41598-019-39968-8. PMID: 30842471; PMCID: PMC6403299.

    Mancuso P, Tricarico R, Bhattacharjee V, Cosentino L, Kadariya Y, Jelinek J, Nicolas E, Einarson M, Beeharry N, Devarajan K, Katz RA, Dorjsuren DG, Sun H, Simeonov A, Giordano A, Testa JR, Davidson G, Davidson I, Larue L, Sobol RW, Yen TJ, Bellacosa A. Thymine DNA glycosylase as a novel target for melanoma. Oncogene. 2019 May;38(19):3710-3728. doi: 10.1038/s41388-018-0640-2. Epub 2019 Jan 23. PMID: 30674989; PMCID: PMC6563616.

    Lulla AR, Slifker MJ, Zhou Y, Lev A, Einarson MB, Dicker DT, El-Deiry WS. miR-6883 Family miRNAs Target CDK4/6 to Induce G1 Phase Cell-Cycle Arrest in Colon Cancer Cells. Cancer Res. 2017 Dec 15;77(24):6902-6913. doi: 10.1158/0008-5472.CAN-17-1767. Epub 2017 Oct 23. PMID: 29061672.

    Beck TN, Korobeynikov VA, Kudinov AE, Georgopoulos R, Solanki NR, Andrews-Hoke M, Kistner TM, Pépin D, Donahoe PK, Nicolas E, Einarson MB, Zhou Y, Boumber Y, Proia DA, Serebriiskii IG, Golemis EA. Anti-Müllerian Hormone Signaling Regulates Epithelial Plasticity and Chemoresistance in Lung Cancer. Cell Rep. 2016 Jul 19;16(3):657-71. doi: 10.1016/j.celrep.2016.06.043. Epub 2016 Jul 7. PMID: 27396341; PMCID: PMC4956518.

     

    Additional Publications

    Bibliography, USNLM

    Resize Text